Current role
Drug Manufacturers - Specialty & Generic · Healthcare
Erik Emerson
Equibles does not estimate personal net worth.
Get an email with a short summary when Apimeds Pharmaceuticals US, Inc. publishes a filing, an earnings call transcript or a press release.
Get APUS alertsAbout Erik Emerson
Apimeds Pharmaceuticals US, Inc. reported in an 8-K filed January 2, 2026 that Erik Emerson was terminated as board of directors, effective December 30, 2025. Apimeds Pharmaceuticals US, Inc. reported in an 8-K filed December 2, 2025 that Erik Emerson was appointed President, effective December 1, 2025. Apimeds Pharmaceuticals US, Inc. reported in an 8-K filed December 2, 2025 that Erik Emerson resigned as Chief Executive Officer, effective December 1, 2025. Apimeds Pharmaceuticals US, Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Apimeds Pharmaceuticals US, Inc. includes Sungjoon Chae (CEO and Board Member), Vin Menon (CEO and Board Member), Youngjik Cho (CEO, Chairman and Board Member) and 4 others.
“On December 30, 2025, the stockholders of Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the "Company"), acting by written consent, removed Erik Emerson from the Company's board of directors, effective as of such date.”
“Also, effective as of the Effective Time, Erik Emerson was appointed to serve as President of the Acquiror.”
Affiliation history
-
Current
2025-12-01–present
Company network
Leadership on record at Apimeds Pharmaceuticals US, Inc.
- Sungjoon Chae CEO, Board Member
- Vin Menon CEO, Board Member
- Youngjik Cho CEO, Chairman, Board Member
- Eric Sherb CFO
- Amir Dossal Board Member
- Junyoung Yu Board Member
- Minguk Ji Board Member